Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells
Angelica Loskog, Valeria Giandomenico, Claudia Rössig, et al.
Leukemia (2006) Vol. 20, Iss. 10, pp. 1819-1828
Closed Access | Times Cited: 190

Showing 1-25 of 190 citing articles:

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito, Michael C. Milone, Raffit Hassan, et al.
Proceedings of the National Academy of Sciences (2009) Vol. 106, Iss. 9, pp. 3360-3365
Open Access | Times Cited: 835
Adoptive T cell therapy for cancer in the clinic
Carl H. June
Journal of Clinical Investigation (2007) Vol. 117, Iss. 6, pp. 1466-1476
Open Access | Times Cited: 545
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
Xiao-Song Zhong, Maiko Matsushita, Jason Plotkin, et al.
Molecular Therapy (2009) Vol. 18, Iss. 2, pp. 413-420
Open Access | Times Cited: 502
The pharmacology of second-generation chimeric antigen receptors
Sjoukje J. C. van der Stegen, Mohamad Hamieh, Michel Sadelain
Nature Reviews Drug Discovery (2015) Vol. 14, Iss. 7, pp. 499-509
Open Access | Times Cited: 488
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon, Carmine Carpenito, Jing Sun, et al.
Clinical Cancer Research (2011) Vol. 17, Iss. 14, pp. 4719-4730
Open Access | Times Cited: 479
Gene-engineered T cells for cancer therapy
Michael H. Kershaw, Jennifer A. Westwood, Phillip K. Darcy
Nature reviews. Cancer (2013) Vol. 13, Iss. 8, pp. 525-541
Closed Access | Times Cited: 467
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive forIn VivoAntitumor Activity
Michael Hudecek, Daniel Sommermeyer, Paula L. Kosasih, et al.
Cancer Immunology Research (2014) Vol. 3, Iss. 2, pp. 125-135
Open Access | Times Cited: 462
The promise and potential pitfalls of chimeric antigen receptors
Michel Sadelain, Renier J. Brentjens, Isabelle Rivière
Current Opinion in Immunology (2009) Vol. 21, Iss. 2, pp. 215-223
Open Access | Times Cited: 453
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Aurore Morello, Michel Sadelain, Prasad S. Adusumilli
Cancer Discovery (2015) Vol. 6, Iss. 2, pp. 133-146
Open Access | Times Cited: 420
Next-generation regulatory T cell therapy
Leonardo M. R. Ferreira, Yannick D. Müller, Jeffrey A. Bluestone, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 10, pp. 749-769
Open Access | Times Cited: 390
Current Progress in CAR-T Cell Therapy for Solid Tumors
Shuo Ma, Xinchun Li, Xinyue Wang, et al.
International Journal of Biological Sciences (2019) Vol. 15, Iss. 12, pp. 2548-2560
Open Access | Times Cited: 380
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
James N. Kochenderfer, Zhiya Yu, Dorina Frasheri, et al.
Blood (2010) Vol. 116, Iss. 19, pp. 3875-3886
Open Access | Times Cited: 350
Chimeric Antigen Receptor Therapy for Cancer
David M. Barrett, Nathan Singh, David L. Porter, et al.
Annual Review of Medicine (2013) Vol. 65, Iss. 1, pp. 333-347
Open Access | Times Cited: 341
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Saar Gill, Carl H. June
Immunological Reviews (2014) Vol. 263, Iss. 1, pp. 68-89
Closed Access | Times Cited: 309
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
Bipulendu Jena, Gianpietro Dotti, Laurence J.N. Cooper
Blood (2010) Vol. 116, Iss. 7, pp. 1035-1044
Open Access | Times Cited: 297
Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL
Xiuli Wang, Leslie Popplewell, Jamie R. Wagner, et al.
Blood (2016) Vol. 127, Iss. 24, pp. 2980-2990
Open Access | Times Cited: 297
Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
Matthew J. Frigault, Ji‐Hyun Lee, Maria C. Basil, et al.
Cancer Immunology Research (2015) Vol. 3, Iss. 4, pp. 356-367
Open Access | Times Cited: 282
CAR-T design: Elements and their synergistic function
Jayapriya Jayaraman, Michael Mellody, Andrew J. Hou, et al.
EBioMedicine (2020) Vol. 58, pp. 102931-102931
Open Access | Times Cited: 248
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Alba Rodríguez-García, Asís Palazón, Estela Noguera-Ortega, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 241
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
Kevin J. Curran, Hollie J. Pegram, Renier J. Brentjens
The Journal of Gene Medicine (2012) Vol. 14, Iss. 6, pp. 405-415
Open Access | Times Cited: 235
Genetically engineered T cells for cancer immunotherapy
Dan Li, Xue Li, Weilin Zhou, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 205
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T
Rachel A. Burga, Mitchell Thorn, Gary R. Point, et al.
Cancer Immunology Immunotherapy (2015) Vol. 64, Iss. 7, pp. 817-829
Open Access | Times Cited: 200
Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
Tseng Hsiang-Chi, Wei Xiong, Saiaditya Badeti, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 144
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy
Carlos A. Ramos, Gianpietro Dotti
Expert Opinion on Biological Therapy (2011) Vol. 11, Iss. 7, pp. 855-873
Open Access | Times Cited: 163
4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies
Syam Tammana, Xin Huang, Marianna Wong, et al.
Human Gene Therapy (2009) Vol. 21, Iss. 1, pp. 75-86
Open Access | Times Cited: 158
Page 1 - Next Page

Scroll to top